psychopharmacology – Page 2

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

mycolabadmin

This review examines how ketamine and psychedelics affect connections between brain cells. Under stressful conditions, ketamine and psychedelics appear to strengthen these connections in brain areas important for mood and learning. However, the effects are mixed under normal conditions and vary based on dose, sex, and which specific markers are measured. The findings suggest these substances may help restore brain function damaged by stress or substance use.

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

mycolabadmin

This comprehensive review explores how psychedelic drugs like psilocybin mushrooms, DMT, and LSD may offer new hope for treating depression, anxiety, and PTSD, especially for patients who don’t respond to conventional antidepressants. Historically used in spiritual ceremonies for thousands of years, these compounds are now being scientifically studied and show promise with fewer side effects than many traditional psychiatric medications. The authors emphasize that while results are encouraging, more research and regulatory approval are needed before these treatments become widely available in mainstream medicine.

Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study

mycolabadmin

Researchers studied how ayahuasca affects memory in experienced Santo Daime church members who use it regularly. Surprisingly, instead of impairing memory like other psychedelics typically do, ayahuasca enhanced people’s ability to remember details of events they witnessed. Importantly, the drug did not make people more susceptible to false memories or memory distortions, even though the entire study occurred while participants were under its acute effects.

Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice

mycolabadmin

This study examined how psilocybin works to reduce anxiety in mice by investigating the role of stress hormones, particularly corticosterone. Researchers found that psilocybin causes a temporary spike in corticosterone levels that is essential for its anxiety-reducing effects hours after administration. Interestingly, other interventions that increase corticosterone levels also produced similar anxiety-reducing effects, suggesting the stress hormone response itself drives the therapeutic benefit rather than psilocybin’s psychedelic properties alone. These findings suggest that measuring cortisol levels in human patients receiving psilocybin therapy could help explain and optimize therapeutic outcomes.

4-Hydroxy-N,N-diisopropyltryptammonium hydrofumarate: Crystal Structure of a Synthetic Psychedelic

mycolabadmin

Scientists have determined the three-dimensional crystal structure of 4-HO-DiPT, a synthetic compound related to psilocin found in magic mushrooms. This is the first crystal structure of this specific compound and provides important structural information for understanding how it works. A related version of this compound is currently being tested in clinical trials for treating postpartum depression and other mood disorders.

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

mycolabadmin

This comprehensive analysis of clinical trials found that psilocybin, a compound found in certain mushrooms, shows promise as a treatment for depression compared to placebo. The treatment was particularly effective for patients with depression related to serious illness, those using self-reported symptom assessments, older adults, and those with prior experience with psychedelics. While side effects were minimal and temporary, researchers emphasize that more research is needed to fully understand how expectancy and individual factors influence treatment outcomes.

Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond

mycolabadmin

Researchers created new chemical versions of psilocybin (the active compound in magic mushrooms) that cannot be broken down by the body’s natural enzymes in the same way. They tested these new compounds to see if they could help with depression and anxiety by targeting specific brain receptors. The best compound worked well on the intended brain receptors but importantly showed less activity on a heart-related receptor, potentially making it safer than natural psilocybin.

Hype or hope? Ketamine for the treatment of depression: results from the application of deep learning to Twitter posts from 2010 to 2023

mycolabadmin

Researchers analyzed over 18,000 Twitter posts from 2010 to 2023 to understand what the public thinks about using ketamine to treat depression. They found that public opinion became much more positive after the FDA approved ketamine as a depression treatment in 2019. Most discussions consisted of personal stories from people who found ketamine helpful, especially those whose depression didn’t respond to other medications. While some people expressed caution and concerns, overall the public seems hopeful about ketamine’s potential.

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

mycolabadmin

This large international study of over 8,700 people found that adults who microdose psychedelics report taking small doses for health and wellness reasons. Among people with anxiety or depression, microdosers showed lower symptom levels than non-microdosers. Most microdosers used psilocybin and combined it with other substances like Lion’s Mane mushrooms or niacin, practices they refer to as stacking.

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults – A Systematic Review

mycolabadmin

Psilocybin, a naturally occurring compound found in certain mushroom species, shows significant promise as a treatment for depression. Clinical studies reviewed in this research found that psilocybin-assisted therapy reduced depressive symptoms in every patient studied, with improvements lasting months after treatment. Unlike traditional antidepressants, psilocybin caused only mild temporary side effects and worked faster, suggesting it could become an important alternative treatment for depression.

Research Topic: psychopharmacology